Study of Two Doses of Crizanlizumab Versus Placebo in Adolescent and Adult Sickle Cell Disease Patients

Running, not enrolling · Phase 3 · Has a placebo group

Conditions studied: Sickle Cell Disease (SCD)

In brief

The purpose of this study is to compare the efficacy and safety of 2 doses of crizanlizumab (5.0 mg/kg and 7.5 mg/kg) versus placebo in adolescent and adult sickle cell disease (SCD) patients with history of vaso-occlusive crisis (VOC) leading to healthcare visit.

Key facts

Study ID
NCT03814746
Run by
Novartis Pharmaceuticals
People needed
255
Starts
2019-07-26
Expected to finish
2026-11-23
Last updated by the study team
2026-07-10

Who can join

Age: 12 and older, up to 100. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.